Skip to content
GC Biopharma
-
GC Biopharma expands Asian footprint with Hunter Syndrome approvals in India, Taiwan
The company said India’s Central Drugs Standard Control Organisation (CDSCO) approved the intravenous (IV) formulation, while Taiwan’s Food and Drug Administration (TFDA) approved both Hunterase IV and Hunterase ICV.